On August 5, 2008, Dr. Rath received an official invitation from the Editor-in-chief of the International Journal of Cancer (IJC), Professor Harald zur Hausen, to become a scientific reviewer for that journal. Prof. zur Hausen is not only the Editor-in-chief of the IJC, but has served for more than two decades as head of the German Cancer Research Centre (DKFZ) in Heidelberg, Germany.
For almost half a century, Prof. zur Hausen has been a prominent voice in the pharmaceutically-oriented cancer research community. His invitation to Dr. Rath, a prominent critic of conventional cancer therapies and a pioneer of natural cancer research, is no coincidence. It reflects the beginning of the re-orientation of international cancer research to specifically include vitamins and other micronutrients in the fight against this epidemic.
This re-orientation was brought about by significant advances in micronutrient research in cancer, a new field of medicine led by Dr. Rath and his research team (www.dr-rath-research.org).
Realizing the significance of this historic moment, Dr. Rath invited the International Journal of Cancer and the German Cancer Research Center to join him – based on the widely available scientific evidence – in a global effort to largely eliminate cancer as a cause of death in future generations.
Following is the full text of Dr. Rath's letter to the Editor-in-chief of the International Journal of Cancer:
Professor Harald zur Hausen
Editor in Chief
International Journal of Cancer
Deutsches Krebsforschungs-Zentrum (DKFZ)
August 13, 2008
Dear Professor zur Hausen,
On August 5, 2008 I received a letter signed by you inviting me to become a reviewer for the International Journal of Cancer (IJC) one of the most influential journals in cancer research. Beside your position as the Editor in Chief of the IJC, you have been chairman of the board of the German Cancer Research Centre (DKFZ) in Heidelberg for two decades, one of the world’s leading cancer research institutions.
In your letter you invite me to review a paper submitted to your journal for publication, documenting the value of ascorbic acid (vitamin C) in the fight against cancer. As the primary reason for this invitation to become a reviewer for your journal you state: “Because of your expertise and experience” in the field of cancer research. I can only interpret this statement as the official recognition of the key role of micronutrients in the control of cancers for which my research team and I have been fighting for more than a decade.
For your entire life you have been a prominent representative of conventional cancer approaches including toxic chemotherapy, radiotherapy and other approaches that primarily served one goal: to use the cancer epidemic as a global market for the pharmaceutical investment business with patented drugs.
For you to contact me – an outspoken critic of these conventional approaches to cancer and a scientific pioneer for new and natural approaches to cancer – was no coincidence. Your decision recognizes two important facts: 1. The deadlocks of pharmaceutically driven approaches to cancer and 2. The compelling perspectives of micronutrients as powerful preventive and therapeutic agents in the control of, essentially, all forms of human cancer.
With your letter you recognize the urgent need for a reorientation of cancer research to specifically include micronutrients in the world-wide fight against cancer. For that decision you should be commended. At the same time, I am fully aware that this step was not voluntary but was compelled by the simple fact that the breathtaking perspective of the natural control of cancer can no longer be ignored. With the world’s media regularly reporting the potential of vitamins and other micronutrients in reversing cancer, the dam is broken.
Considering the magnitude of negligence and obstruction towards micronutrients from the side of pharmaceutical medicine and considering the deadly consequences of this opposition for millions of cancer patients, your letter marks a turning point. It is obvious, however, that such a turning point in history cannot be guided by those who share responsibility for – or have at least tolerated – one of the darkest chapters in the history of mankind: the medical genocide in cancer.
In this situation, I have decided to respond to your letter in the form of an Open Letter to be shared with those most concerned about the way forward: The millions of cancer patients around the world. I am addressing you:
Before outlining the way forward, I consider it my duty to raise some of the questions from a consternated and outraged public you and your colleagues will have to answer in the months to come:
While the truth about the life-saving role of micronutrients in the fight against cancer was obstructed over decades, more than six million cancer patients worldwide died each year. They paid the ultimate price for the obstruction of the truth in the interests of the pharmaceutical investment business with the cancer epidemic. In light of this historic failure it would be naïve to think that a solution can come from those researchers that were largely responsible for this tragedy – or at least tolerated it.
In the interest of millions of cancer patients I therefore consider it incumbent upon me to direct the way forward. Here is what needs to be done immediately:
In the interest of millions of people, these tasks need to be tackled immediately. Considering the immense task to redirect cancer research on a global level, your invitation for me to join your journal as a reviewer is a drop in the ocean.
I am inviting you and your research colleagues to join us in a vigorous international effort with the defined goal to end the cancer epidemic forever. The scientific rationale to reach this goal is available. What needs to be done now is to organize a global effort to end cancer, involving science, medicine, politics and all other sectors of society.
With millions of lives at stake, if you stay indifferent now, history will judge you. If you decide to act, we will join our forces towards this great goal all mankind has been waiting for. If this is the goal, my research team and I are ready to cooperate with your journal and your research colleagues at every level.
As a first step we propose to jointly organize a public symposium between your journal, the DKFZ and our research institute. At this symposium the best researchers from the DKFZ and from our research team would present their research to an audience of patients, doctors and the public at large. Such a symposium could serve as the beginning of an international campaign carried by our research institutes and others who will join us towards the eradication of cancer.
I am looking forward to your response.
Matthias Rath, M.D.